

PERKINS DISCOVERY FUND

Schedule of Investments

December 31, 2022 (unaudited)

	<u>Shares</u>	<u>Fair Value</u>
98.21% COMMON STOCKS		
1.42% BIOTECHNOLOGY		
Journey Medical Corp. ^(A)	22,000	\$ 42,240
MDXHealth SA ^(A)	11,000	<u>65,340</u>
		<u>107,580</u>
9.13% CONSUMER DISCRETIONARY		
iMedia Brands, Inc. ^(A)	35,700	22,848
Magnite, Inc. ^(A)	20,000	211,800
Perion Network Ltd. ^(A)	18,000	<u>455,400</u>
		<u>690,048</u>
1.16% FINANCIALS		
FlexShopper, Inc. ^(A)	93,500	<u>87,338</u>
20.11% HEALTH CARE DRUGS/SERVICES		
ANI Pharmaceuticals, Inc. ^(A)	7,100	285,633
NeoGenomics, Inc. ^(A)	22,000	203,280
Paratek Pharmaceuticals, Inc. ^(A)	32,000	59,840
Veracyte, Inc. ^(A)	21,500	510,195
Vericel Corp. ^(A)	17,500	<u>460,950</u>
		<u>1,519,898</u>
5.87% HEALTH CARE MANUFACTURING		
AtriCure, Inc. ^(A)	10,000	<u>443,800</u>
11.09% HEALTH CARE SUPPLIES		
Axogen, Inc. ^(A)	32,500	324,350
BioLife Solutions, Inc. ^(A)	16,500	300,300
Cryoport, Inc. ^(A)	10,000	173,500
Exagen, Inc. ^(A)	16,500	<u>39,600</u>
		<u>837,750</u>

PERKINS DISCOVERY FUND

Schedule of Investments - continued

December 31, 2022 (unaudited)

	Shares	Fair Value
12.93% HEALTH CARE SUPPORT		
Natera, Inc. ^(A)	11,500	\$ 461,955
Option Care Health, Inc. ^(A)	16,500	496,485
Rockwell Medical, Inc. ^(A)	18,181	18,454
		976,894
7.34% HEALTH CARE TECHNOLOGY		
Fortress Biotech, Inc. ^(A)	69,500	45,522
IsoRay, Inc. ^(A)	200,000	49,420
OptimizeRx Corp. ^(A)	15,000	252,000
Streamline Health Solutions, Inc. ^(A)	131,500	207,770
		554,712
18.05% INFORMATION TECHNOLOGY		
Airgain, Inc. ^(A)	15,500	100,905
Akoustis Technologies, Inc. ^(A)	29,000	81,780
Cantaloupe, Inc. ^(A)	43,000	187,050
Digi International, Inc. ^(A)	13,200	482,460
Inuvo, Inc. ^(A)	514,500	113,962
Perficient, Inc. ^(A)	5,700	398,031
		1,364,188
11.11% SOFTWARE SERVICES		
Asure Software, Inc. ^(A)	33,000	308,220
ePlus, Inc. ^(A)	12,000	531,360
		839,580
98.21% TOTAL COMMON STOCKS		\$ 7,421,788
3.94% SHORT-TERM INVESTMENTS		
Fidelity Investments Money Market Government Portfolio		
Institutional Class 4.06% ^(B)	298,006	\$ 298,006
102.15% TOTAL INVESTMENTS		7,719,794
(2.15%) Liabilities in excess of other assets		(162,670)
100.00% NET ASSETS		\$ 7,557,124

^(A) Non-income producing

^(B) Effective 7 day yield as of December 31, 2022

PERKINS DISCOVERY FUND

Schedule of Investments - continued

December 31, 2022 (unaudited)

In accordance with U.S. GAAP, “fair value” is defined as the price that a Fund would receive upon selling an investment in an orderly transaction to an independent buyer in the principal or most advantageous market for the investment. Various inputs are used in determining the value of a Fund’s investments. U.S. GAAP established a three-tier hierarchy of inputs to establish a classification of fair value measurements for disclosure purposes. Level 1 includes quoted prices in active markets for identical securities. Level 2 includes other significant observable inputs (including quoted prices for similar securities, interest rates, prepayment speeds, credit risk, etc.). Level 3 includes significant unobservable inputs (including the Fund’s own assumptions in determining fair value of investments).

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

The following is a summary of the inputs used to value the Fund’s investments as of December 31, 2022:

	Level 1	Level 2	Level 3	
	Quoted Prices	Other Significant Observable Inputs	Significant Unobservable Inputs	Total
Common Stocks	\$7,421,788	\$ —	\$ —	\$7,421,788
Short-Term Investments	298,006	—	—	298,006
Total Investments	\$7,719,794	\$ —	\$ —	\$7,719,794

The Fund held no Level 3 securities at any time during the period.

There were no transfers into or out of Levels 1 and 2 during the period ended December 31, 2022.

At December 31, 2022, the cost of investments for Federal income tax purposes has been estimated since the final tax characteristics cannot be determined until fiscal year end. Cost of securities for Federal income tax purpose is \$5,868,940 and the related tax-based net unrealized appreciation (depreciation) consists of:

Gross unrealized appreciation	\$ 3,919,137
Gross unrealized depreciation	(2,068,283)
Net unrealized appreciation	\$ 1,850,854